Skip to main navigation Skip to search Skip to main content

Histone acetylation and disease

  • CNRS UPR 9079 Oncogénèse, Différenciation et Transduction du Signal

Research output: Contribution to journalReview articlepeer-review

Abstract

Differential acetylation of histones and transcription factors plays an important regulatory role in developmental processes, proliferation and differentiation. Aberrant acetylation or deacetylation leads to such diverse disorders as leukemia, epithelial cancers, fragile X syndrome and Rubinstein-Taybi syndrome. The various groups of histone acetyltransferases (CBP/p300, GNAT, MYST, nuclear receptor coactivators and TAFII250) and histone deacetylases are surveyed with regard to their possible or known involvement in cancer progression and human developmental disorders. Current treatment strategies are discussed, which are still mostly limited to histone deacetylase inhibitors such as trichostatin A and butyrate.

Original languageEnglish
Pages (from-to)728-736
Number of pages9
JournalCellular and Molecular Life Sciences
Volume58
Issue number5-6
DOIs
Publication statusPublished - 1 Jan 2001
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Butyrate
  • Dietary fiber
  • Fragile X syndrome
  • HAT
  • HDAC
  • Histone acetylation
  • Leukemia
  • TSA

Fingerprint

Dive into the research topics of 'Histone acetylation and disease'. Together they form a unique fingerprint.

Cite this